Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/30481
Tipo de documento
ArtigoDireito Autoral
Acesso restrito
Data de embargo
2028-08-30
Coleções
- INI - Artigos de Periódicos [3399]
Metadata
Mostrar registro completo
ONCE-DAILY ATAZANAVIR/RITONAVIR VERSUS TWICE-DAILY LOPINAVIR/RITONAVIR, EACH IN COMBINATION WITH TENOFOVIR AND EMTRICITABINE, FOR MANAGEMENT OF ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS: 48 WEEK EFFICACY AND SAFETY RESULTS OF THE CASTLE STUDY
Autor(es)
Afiliação
Saint-Louis Hospital. Department of Infectious Diseases. Paris./ University of Paris-Diderot, Paris, France.
Hospital Civil de Guadalajara. Guadalajara, Mexico.
Hospital Nacional Cayetano Heredia. Lima, Peru.
Khonkaen University. Department of Medicine. Khonkaen, Thailand.
Hospital Interzonal Gral De Agudos Oscar Alende. Buenos Aires, Argentina.
Brooklyn Medical Centre. Western Cape, South Africa.
Chelsea and Westminster Hospital. London, UK.
Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA.
Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA.
Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA.
Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA.
Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA.
Hospital Civil de Guadalajara. Guadalajara, Mexico.
Hospital Nacional Cayetano Heredia. Lima, Peru.
Khonkaen University. Department of Medicine. Khonkaen, Thailand.
Hospital Interzonal Gral De Agudos Oscar Alende. Buenos Aires, Argentina.
Brooklyn Medical Centre. Western Cape, South Africa.
Chelsea and Westminster Hospital. London, UK.
Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA.
Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA.
Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA.
Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA.
Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA.
Resumo em Inglês
Atazanavir/ritonavir is as effective as lopinavir/ritonavir, with a more favourable lipid profile and less gastrointestinal toxicity, in treatment-experienced HIV-1-infected patients. We compared these two combinations directly in treatment-naive patients.
Compartilhar